Lantern Pharma Inc
LTRN
查看详细走势图
3.260USD
+0.020+0.62%
收盘 12/19, 16:00（美东）报价延迟15分钟
35.99M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.62%
5天
-9.44%
1月
+8.67%
6月
+2.52%
今年开始到现在
+2.19%
1年
+3.66%
查看详细走势图
TradingKey Lantern Pharma Inc股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值合理，机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Lantern Pharma Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
1
位分析师
买入
评级
20.000
目标均价
+419.48%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Lantern Pharma Inc亮点
亮点风险
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值高估
公司最新PE估值-2.27，处于3年历史高位
机构减仓
最新机构持股2.26M股，环比减少17.91%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值90.60K
活跃度降低
近期活跃度降低，过去20天平均换手率0.11
Lantern Pharma Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Lantern Pharma Inc简介
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
公司代码LTRN
公司Lantern Pharma Inc
CEOSharma (Panna L)
网址https://www.lanternpharma.com/
常见问题
Lantern Pharma Inc(LTRN)的当前股价是多少？
Lantern Pharma Inc(LTRN)的当前股价是 3.260。
Lantern Pharma Inc的股票代码是什么？
Lantern Pharma Inc的股票代码是LTRN。
Lantern Pharma Inc股票的52周最高点是多少？
Lantern Pharma Inc股票的52周最高点是6.118。
Lantern Pharma Inc股票的52周最低点是多少？
Lantern Pharma Inc股票的52周最低点是2.550。
Lantern Pharma Inc的市值是多少？
Lantern Pharma Inc的市值是35.99M。
Lantern Pharma Inc的净利润是多少？
Lantern Pharma Inc的净利润为-20.78M。
现在Lantern Pharma Inc(LTRN)的股票是买入、持有还是卖出？
根据分析师评级，Lantern Pharma Inc(LTRN)的总体评级为买入，目标价格为20.000。
Lantern Pharma Inc(LTRN)股票的每股收益（EPS TTM）是多少
Lantern Pharma Inc(LTRN)股票的每股收益（EPS TTM）是-1.753。
相关品种
